GALT
Galectin Therapeutics Inc.
$2.57
-$0.13(-4.81%)
35
Overall
40
Value
50
Tech
15
Quality
Market Cap
$376.03M
Volume
348.77K
52W Range
$1.21 - $7.13
Target Price
$11.00
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-21.5M | $-16.2M | $-13.6M | $13.4M | $23.4M | $30.2M | $38.4M | $38.1M | $42.4M | $20.1M | ||
| Research & Development | $15.3M | $11.7M | $6.5M | $7.5M | $18.0M | $23.8M | $31.7M | $32.1M | $36.6M | $14.3M | ||
| Research Expense | $15.3M | $11.7M | $6.5M | $7.5M | $18.0M | $23.8M | $31.7M | $32.1M | $36.6M | $14.3M | ||
| Selling, General & Administrative | $6.2M | $4.5M | $7.1M | $6.0M | $5.5M | $6.4M | $6.6M | $5.9M | $5.9M | $5.8M | ||
| General & Administrative Expenses | $6.2M | $4.5M | $7.1M | $6.0M | $5.5M | $6.4M | $6.6M | $5.9M | $5.9M | $5.8M | ||
| Salaries & Wages | -- | -- | $-4.4M | $-1.7M | $1.8M | -- | -- | $2.3M | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | -- | -- | -- | -- | $38.1M | -- | $20.1M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-21.5M | $-16.2M | $-13.6M | $-13.4M | $-23.4M | $-30.2M | $-38.4M | $-38.1M | $-42.4M | $-20.1M | ||
| EBITDA | $-21.4M | $-16.2M | $-13.6M | $-13.2M | $-23.3M | $-30.0M | $-37.7M | $-41.0M | $-41.5M | $-23.5M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | $12.0K | $336.0K | $87.0K | $87.0K | $489.0K | $1.0M | $2.8M | $5.5M | $7.3M | ||
| Intinc | $45.0K | $24.0K | $38.0K | $231.0K | $66.0K | $3.0K | $52.0K | $230.0K | $338.0K | $126.0K | ||
| Net Non-Operating Interest Income/Expense | $45.0K | $12.0K | $-298.0K | $144.0K | $-21.0K | $-486.0K | $-981.0K | $230.0K | $-5.2M | $-7.2M | ||
| Gain on Sale of Securities | -- | -- | -- | -- | -- | $138.0K | $557.0K | $-432.0K | $588.0K | $-3.5M | ||
| Other Income/Expense | -- | -- | -- | -- | -- | $-138.0K | $557.0K | $432.0K | $-588.0K | $3.5M | ||
| Other Special Charges | -- | -- | -- | -- | -- | $138.0K | $557.0K | $-3.0M | -- | $-10.8M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-21.4M | $-16.2M | $-13.6M | $-13.2M | $-23.4M | $-30.0M | $-37.7M | $-41.1M | $-41.5M | $-23.5M | ||
| Pre-Tax Income | $-21.4M | $-16.2M | $-13.9M | $-13.3M | $-23.5M | $-30.5M | $-38.8M | $-38.3M | $-47.0M | $-30.8M | ||
| NET INCOME | ||||||||||||
| Net Income | $-21.4M | $-16.2M | $-13.9M | $-13.3M | $-23.5M | $-30.5M | $-38.8M | $-41.1M | $-47.0M | $-30.8M | ||
| Net Income (Continuing Operations) | $-21.4M | $-16.2M | $-13.9M | $-13.3M | $-23.5M | $-30.5M | $-38.8M | $-41.1M | $-47.0M | $-30.8M | ||
| Net Income (Discontinued Operations) | $-21.4M | $-16.2M | $-13.9M | $-13.3M | $-23.5M | $-30.5M | $-38.8M | $-41.1M | $-47.0M | $-30.8M | ||
| Net Income (Common Stockholders) | $-22.4M | $-17.5M | $-15.0M | $-20.2M | $-23.6M | $-30.7M | $-38.9M | $-44.8M | $-47.2M | $-31.0M | ||
| Normalized Income | -- | -- | -- | -- | -- | $-24.1M | -- | -- | -- | $-30.5M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-21.5M | $-16.2M | $-13.6M | $13.4M | $23.4M | $30.2M | $38.4M | $38.1M | $42.4M | $20.1M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $29.2M | $35.5M | $39.4M | $52.2M | $57.0M | $58.5M | $59.4M | $60.2M | $62.3M | $63.9M | ||
| Average Shares Outstanding (Diluted) | $28.1M | $33.1M | $36.6M | $52.2M | $57.0M | $58.5M | $59.4M | $60.2M | $62.3M | $63.9M | ||
| Shares Outstanding | $34.1M | $37.6M | $45.6M | $57.0M | $57.2M | $59.4M | $59.4M | $61.9M | $63.2M | $65.8M | ||
| Basic EPS | -- | -- | -- | -- | $-0.41 | $-0.52 | $-0.65 | $-0.74 | $-0.76 | $-0.48 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-0.41 | $-0.52 | $-0.65 | $-0.74 | $-0.76 | $-0.48 | ||
| Diluted EPS | $-0.76 | $-0.49 | $-0.38 | $-0.39 | $-0.41 | $-0.52 | $-0.65 | $-0.74 | $-0.76 | $-0.48 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $-0.39 | -- | $-0.52 | $-0.65 | $-0.74 | $-0.76 | $-0.48 | ||
| OTHER METRICS | ||||||||||||
| Accretion On Preferred Stock | $173.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Accrued Preferred Stock Dividends | $741.0K | $1.2M | $1.1M | $6.9M | $137.0K | $171.0K | $97.0K | $120.0K | $153.0K | $138.0K | ||
| Other Gand A | $6.2M | $4.5M | $7.1M | $6.0M | $5.5M | $6.4M | $6.6M | $5.9M | $5.9M | $5.8M | ||
| Preferred Stock Dividends | $914.0K | $1.2M | $1.1M | $6.9M | $137.0K | $171.0K | $97.0K | $120.0K | $153.0K | $138.0K | ||
| Rent And Landing Fees | $6.2M | $4.5M | $7.1M | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GALT | $2.57 | -4.8% | 348.77K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Galectin Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW